Artículos utilizados:

​

1.          Devinsky O, Whalley BJ, Di Marzo V. Cannabinoids in the Treatment of Neurological Disorders. Neurotherapeutics. 2015;12(4):689-691. doi:10.1007/s13311-015-0388-0.

​

2.           Aso E, Ferrer I. Cannabinoids for treatment of alzheimer’s disease: Moving toward the clinic. Front Pharmacol. 2014;5 MAR(March):1-11. doi:10.3389/fphar.2014.00037.

​

3.           Walther S, Halpern M. Cannabinoids and dementia: A review of clinical and preclinical data. Pharmaceuticals. 2010;3(8):2689-2708. doi:10.3390/ph3082689.

​

4.           Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2(October 2011). doi:10.1038/tp.2012.15.

​

5.           Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669-1678. doi:10.1503/cmaj.071178.

​

6.           Ishiguro H, Horiuchi Y, Ishikawa M, et al. Brain Cannabinoid CB2 Receptor in Schizophrenia. Biol Psychiatry. 2010;67(10):974-982. doi:10.1016/j.biopsych.2009.09.024.

​

7.           Koppel BS, Brust JCM, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563. doi:10.1212/WNL.0000000000000363.

​

8.           Gould GG, Seillier A, Weiss G, et al. Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog Neuro-Psychopharmacology Biol Psychiatry. 2012;38(2):260-269. doi:10.1016/j.pnpbp.2012.04.011.

​

9.           Ferretjans R, De Campos SM, Ribeiro-Santos R, et al. Cognitive performance and peripheral endocannabinoid system receptor expression in schizophrenia. Schizophr Res. 2014;156(2-3):254-260. doi:10.1016/j.schres.2014.04.028.

​

10.        Jenko KJ, Hirvonen J, Henter ID, et al. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr Res. 2012;141(2-3):185-188. doi:10.1016/j.schres.2012.07.021.

​

11.        Katsuyama S, Mizoguchi H, Komatsu T, Nagaoka K, Sakurada S, Sakurada T. The cannabinoid 1 receptor antagonist AM251 produces nocifensive behavior via activation of ERK signaling pathway. Neuropharmacology. 2010;59(6):534-541. doi:10.1016/j.neuropharm.2010.07.015.

​

12.        Wong DF, Kuwabara H, Horti AG, et al. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage. 2010;52(4):1505-1513. doi:10.1016/j.neuroimage.2010.04.034.

​

13.        Concannon RM, Okine BN, Finn DP, Dowd E. Differential upregulation of the cannabinoid CB<inf>2</inf> receptor in neurotoxic and inflammation-driven rat models of Parkinson’s disease. Exp Neurol. 2015;269:133-141. doi:10.1016/j.expneurol.2015.04.007.

​

14.    Universidad de Caldas. Departamento de Salud Pública. JH, Thomson Gale (Firm) HF. Cannabis, una opción terapéutica. Biosalud. 2002;8(1):166-177. http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S1657- ​

​

15.      Meyer J, Quenzer L. Psychopharmacology: Drugs, the Brain and Behavioral. second edition. Sunderland, MA: Sinauer Associates, Inc.; 2013.

​

16.     Watt G, Karl T. In vivo evidence for therapeutic properties of cannabidiol (CBD)  for alzheimer’s disease. Front Pharmacol. 2017;8(FEB):1-7. doi:10.3389/fphar.2017.00020.

​

17.    Alper BS, Manheimer EW, Ehrlich A. Point of care application: “Trial of cannabidiol for drug resistant seizures in the Dravet syndrome.” Eur J Integr Med. 2017;14:20 21. doi:10.1016/j.eujim.2017.08.002.

​

18.    Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. 2007;152(5):649-654.doi:10.1038/sj.bjp.0707458.

​